{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:14:59Z","timestamp":1782814499392,"version":"3.54.5"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7010","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T22:25:09Z","timestamp":1485901509000},"page":"335-339","source":"Crossref","is-referenced-by-count":8,"title":["Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine"],"prefix":"10.2169","volume":"56","author":[{"given":"Kenji","family":"Iwaku","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Showa-University Fujigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Otuka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Showa-University Fujigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matsuo","family":"Taniyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Showa-University Fujigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41, 2009.","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223, 2005.","DOI":"10.1056\/NEJMoa051688"},{"key":"3","unstructured":"3. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 (Suppl): 1-56, 2004."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lipscombe LL, Austin PC, Alessi-Severini S, et al. Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Atypical antipsychotics and hyperglycemic emergencies: Multicentre, retrospective cohort study of administrative data. Schizophr Res 154: 54-60, 2014.","DOI":"10.1016\/j.schres.2014.01.043"},{"key":"5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1592\/phco.22.11.841.33629","volume":"22","author":"EA Koller","year":"2002","unstructured":"5. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22: 841-852, 2002.","journal-title":"Pharmacotherapy Official Journal of the American College of Clinical Pharmacy","ISSN":"https:\/\/id.crossref.org\/issn\/0277-0008","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159: 561-566, 2002.","DOI":"10.1176\/appi.ajp.159.4.561"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yasui-Furukori N, Sato Y, Furukori H, Saito M, Nakagami T, Kaneko S. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. J Clin Psychiatry 70: 95-100, 2009.","DOI":"10.4088\/JCP.07m03829"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 68: 533-541, 2007.","DOI":"10.4088\/JCP.v68n0407"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 164: 672-681, 2006.","DOI":"10.1093\/aje\/kwj289"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ely SF, Neitzel AR, Gill JR. Fatal diabetic ketoacidosis and antipsychotic medication. J Forensic Sci 58: 398-403, 2013.","DOI":"10.1111\/1556-4029.12044"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Saf 30: 589-599, 2007.","DOI":"10.2165\/00002018-200730070-00004"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy 21: 1448-1454, 2001.","DOI":"10.1592\/phco.21.17.1448.34421"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314: 1360-1368, 1986.","DOI":"10.1056\/NEJM198605223142106"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331: 1428-1436, 1994.","DOI":"10.1056\/NEJM199411243312107"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221-229, 2001.","DOI":"10.1016\/S0140-6736(01)05415-0"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Daneman D. Type 1 diabetes. Lancet 367: 847-858, 2006.","DOI":"10.1016\/S0140-6736(06)68341-4"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 383: 69-82, 2014.","DOI":"10.1016\/S0140-6736(13)60591-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Abdul-Rasoul M, Habib H, Al-Khouly M. The honeymoon phase&apos; in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes 7: 101-107, 2006.","DOI":"10.1111\/j.1399-543X.2006.00155.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. T\u00f6rn C, Landin-Olsson M, Lernmark A, et al. Prognostic factors for the course of beta cell function in autoimmune diabetes. JCEM 85: 4619-4623, 2000.","DOI":"10.1210\/jc.85.12.4619"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bonifacio E, Bingley PJ, Shattock M, et al. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 335: 147-149, 1990.","DOI":"10.1016\/0140-6736(90)90013-U"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kawasaki E, Maruyama T, Imagawa A, et al. Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus. J Diabetes Investig 5: 115-118, 2014.","DOI":"10.1111\/jdi.12119"},{"key":"22","unstructured":"22. Lombardo F, Valenzise M, Wasniewska M, et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab 15: 246-251, 2002."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther 125: 169-179, 2010.","DOI":"10.1016\/j.pharmthera.2009.10.010"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bonhaus DW, Weinhardt KK, Taylor M, et al. RS-102221: a novelhighaffinity and selective, 5-HT2Creceptorantagonist. Neuropharmacology 36: 621-629, 1997.","DOI":"10.1016\/S0028-3908(97)00049-X"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 100: 70-85, 2008.","DOI":"10.1016\/j.schres.2007.11.026"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mizrahi R, Rusjan P, Agid O, et al. Adversesubjectiveexperience with antipsychotics and its relationship to striatal and extrastriatalD2receptors: a PETstudy in schizophrenia. Am J Psychiatry 164: 630-637, 2007.","DOI":"10.1176\/ajp.2007.164.4.630"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ozasa R, Okada T, Nadanaka S, et al. The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic \u03b2 cells by blocking PERK-mediated translational attenuation. Cell Struct Funct 38: 183-195, 2013.","DOI":"10.1247\/csf.13012"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Engl J, Laimer M, Niederwanger A, et al. Olanzapineimpairsglycogensynthesis and insulinsignaling in L6skeletalmusclecells. Mol Psychiatry 10: 1089-1096, 2005.","DOI":"10.1038\/sj.mp.4001729"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/3\/56_56.7010\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T04:24:26Z","timestamp":1568780666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/3\/56_56.7010\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7010","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}